KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2025)

Historic Finished Goods for Sarepta Therapeutics (SRPT) over the last 10 years, with Q3 2025 value amounting to $64.8 million.

  • Sarepta Therapeutics' Finished Goods fell 1689.98% to $64.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.8 million, marking a year-over-year decrease of 1689.98%. This contributed to the annual value of $47.2 million for FY2024, which is 2361.74% down from last year.
  • Sarepta Therapeutics' Finished Goods amounted to $64.8 million in Q3 2025, which was down 1689.98% from $71.0 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Finished Goods high stood at $78.0 million for Q3 2024, and its period low was $26.7 million during Q4 2021.
  • Moreover, its 5-year median value for Finished Goods was $47.2 million (2024), whereas its average is $46.4 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Finished Goods surged by 71344.19% in 2021, and later plummeted by 2361.74% in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Finished Goods (Quarter) stood at $26.7 million in 2021, then surged by 42.78% to $38.1 million in 2022, then soared by 62.02% to $61.8 million in 2023, then dropped by 23.62% to $47.2 million in 2024, then skyrocketed by 37.27% to $64.8 million in 2025.
  • Its Finished Goods was $64.8 million in Q3 2025, compared to $71.0 million in Q2 2025 and $61.4 million in Q1 2025.